FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:879-885 September 20, 2001 Number 12 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Infection with the larval form of the pork tapeworm, Taenia solium, can lead to the development of cysts in the brain. Surgical removal of cysts has been the accepted treatment for neurocysticercosis characterized by giant cysts when there is associated intracranial hypertension.

Methods We describe 33 patients whom we treated medically for malignant forms of neurocysticercosis. All patients had evidence of intracranial hypertension and subarachnoid cysts at least 50 mm in diameter. All patients received 15 mg of albendazole per kilogram of body weight per day for four weeks. Ten patients were also treated with 100 mg of praziquantel per kilogram per day for four weeks. Seventeen patients received a second course of albendazole, three received a third course, and one received a fourth course. During the first cycle of treatment, all patients also received dexamethasone. Five patients had previously undergone neurosurgery for giant cysts.

Results After a median of 59 months of follow-up (range, 7 to 102), the condition of all 33 patients had improved, and the cysts had disappeared or become calcified. Of the 22 patients with a history of seizures, only 11 continued to receive antiseizure medications. The median quality-of-life score on the Karnofsky scale improved from 40 to 100. Fifteen patients received a ventriculoperitoneal shunt because of hydrocephalus. Four patients had persistent sequelae (bilateral partial optic atrophy, stroke, or diplopia) of the cysts.

Conclusions Intensive medical treatment can be effective in patients with neurocysticercosis characterized by giant cysts. Neurosurgery may be required only when there is an imminent risk of death.

Source Information

From the Medical Research Unit for Neurologic Diseases (J.V.P., I.M., I.G.) and the Departments of Imaging (F.A., G.D.) and Neurosurgery (B.L.-F.), Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexican Institute of Social Security, Mexico City, Mexico.

Address reprint requests to Dr. Proaño at Santiago Valverde No. 68, Col. Presidentes Ejidales, C.P. 04470, México D.F., Mexico, or at proanio_00{at}yahoo.com.

Full Text of this Article

This article has been cited by other articles:

• Nash, T. E., Singh, G., White, A. C., Rajshekhar, V., Loeb, J. A., Proano, J. V., Takayanagui, O. M., Gonzalez, A. E., Butman, J. A., DeGiorgio, C., Del Brutto, O. H., Delgado-Escueta, A., Evans, C.A.W., Gilman, R. H., Martinez, S. M., Medina, M. T., Pretell, E. J., Teale, J., Garcia, H. H. (2006). Treatment of neurocysticercosis: current status and future research needs.. Neurology 67: 1120-1127 [Abstract] [Full Text]  
• Garcia, H. H, Gonzalez, A. E, Tsang, V. C W, Gilman, R. H, for the Cysticerocosis Working Group in Peru, (2006). Neurocysticercosis: some of the essentials. PN 6: 288-297 [Full Text]  
• Gongora-Rivera, F., Soto-Hernandez, J. L., Esquivel, D. G., Cook, H. J., Marquez-Caraveo, C., Davila, R. H., Santos-Zambrano, J. (2006). Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 66: 436-438 [Abstract] [Full Text]  
• GARCIA, H. H., DEL BRUTTO, O. H., NASH, T. E., WHITE, A. C. JR., TSANG, V. C. W., GILMAN, R. H. (2005). NEW CONCEPTS IN THE DIAGNOSIS AND MANAGEMENT OF NEUROCYSTICERCOSIS (TAENIA SOLIUM). Am J Trop Med Hyg 72: 3-9 [Abstract] [Full Text]  
• Singhi, P., Singhi, S. (2004). Topical Review: Neurocysticercosis in Children. J Child Neurol 19: 482-492 [Abstract]  
• Marquez-Caraveo, C, Gongora-Rivera, F, Santos Zambrano, J, Hernandez, R, Soto-Hernandez, J L (2004). Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J. Neurol. Neurosurg. Psychiatry 75: 938-939 [Full Text]  
• Braga, F., Rocha, A. J., Gomes, H. R., Filho, G. H., Silva, C. J., Fonseca, R. B. (2004). Noninvasive MR Cisternography with Fluid-Attenuated Inversion Recovery and 100% Supplemental O2 in the Evaluation of Neurocysticercosis. Am. J. Neuroradiol. 25: 295-297 [Abstract] [Full Text]  
• Garcia, H. H., Pretell, E. J., Gilman, R. H., Martinez, S. M., Moulton, L. H., Del Brutto, O. H., Herrera, G., Evans, C. A.W., Gonzalez, A. E., the Cysticercosis Working Group in Peru, (2004). A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis. NEJM 350: 249-258 [Abstract] [Full Text]  
• Sotelo, J. (2004). Neurocysticercosis -- Is the Elimination of Parasites Beneficial?. NEJM 350: 280-282 [Full Text]  
• Sotelo, J. (2003). Neurocysticercosis. BMJ 326: 511-512 [Full Text]  
• Garcia, H. H., Evans, C. A. W., Nash, T. E., Takayanagui, O. M., White, A. C. Jr., Botero, D., Rajshekhar, V., Tsang, V. C. W., Schantz, P. M., Allan, J. C., Flisser, A., Correa, D., Sarti, E., Friedland, J. S., Martinez, S. M., Gonzalez, A. E., Gilman, R. H., Del Brutto, O. H. (2002). Current Consensus Guidelines for Treatment of Neurocysticercosis. Clin. Microbiol. Rev. 15: 747-756 [Abstract] [Full Text]